MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an
Synergistic collaboration to revolutionize age-related therapies worldwideDeal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ Turn Biotechnologies
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease balticbusinessnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from balticbusinessnews.com Daily Mail and Mail on Sunday newspapers.
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.